Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has issued an announcement.
Lumos Diagnostics Holdings Ltd has applied for quotation on the ASX of 768,159 new ordinary fully paid shares, to be issued on 5 February 2026 under its code LDX. The additional securities, arising from the exercise or conversion of existing options or other convertible instruments, will modestly expand the company’s share base and provide incremental capital or facilitate incentive arrangements, signalling ongoing corporate activity as Lumos seeks to support its operations and growth within the diagnostics sector.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd is an Australian-listed medical diagnostics company that develops and manufactures rapid point-of-care diagnostic solutions, typically serving healthcare and related markets that require quick, accurate testing at or near the patient site.
Average Trading Volume: 4,295,380
Technical Sentiment Signal: Buy
Current Market Cap: A$214M
For a thorough assessment of LDX stock, go to TipRanks’ Stock Analysis page.